Key Highlights

  • Biomea Fusion finalized enrollment of 64 subjects for its Phase 2 COVALENT-211 trial.
  • The trial evaluates icovamenib in insulin-deficient type 2 diabetes.
  • Topline results for the 26-week primary endpoint are slated for Q1 2027.
  • A separate Phase 2 arm targeting GLP-1-inadequate responders continues recruitment, with data anticipated in Q2 2027.

Biomea Fusion, Inc. (NASDAQ: BMEA) successfully finalized enrollment of 64 subjects for its Phase 2 COVALENT-211 trial evaluating icovamenib in insulin-deficient type 2 diabetes.

What Happened

Topline results for the 26-week primary endpoint are slated for Q1 2027, while a separate Phase 2 arm targeting GLP-1-inadequate responders continues recruitment, with data anticipated in Q2 2027.

Market Reaction

The disclosed information does not include stock price or trading data for Biomea Fusion following the enrollment completion.

Outlook

Topline data from COVALENT-211, expected in Q1 2027, and results from the GLP-1 inadequate-response cohort, expected in Q2 2027, represent the next major disclosed milestones for icovamenib.